Hangzhou
China
14
2025-02-06
7
2022-06-21
These are the the leading inventors for applications assigned to BETTA PHARMACEUTICALS CO., LTD.:
BETTA PHARMACEUTICALS CO., LTD. based in Hangzhou, CN has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
BICYCLIC COMPOUND AND APPLICATION THEREOF
#2 | 2024-11-21BISPECIFIC ANTIBODY AND APPLICATION THEREOF
#3 | 2024-10-24SALT AND CRYSTAL FORM OF EGFR INHIBITOR, AND COMPOSITION AND USE THEREOF
#4 | 2024-10-17USE OF ENSARTINIB OR SALT THEREOF IN TREATMENT OF DISEASE CARRYING MET 14 EXON SKIPPING MUTATION
#5 | 2024-10-03ANTI-PD-L1 NANOBODY AND USE THEREOF
#6 | 2024-05-30SALT AND CRYSTALLINE FORMS OF FGFR4 INHIBITOR AND USES THEREOF
#7 | 2023-02-23IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
#8 | 2021-05-06 ✅ Patent 11,365,196 granted on 2022-06-21FGFR inhibitor and application thereof
#9 | 2018-01-11 ✅ Patent 10,059,688 granted on 2018-08-28Protein tyrosine kinase modulators and methods of use
#10 | 2016-05-19 ✅ Patent 9,505,774 granted on 2016-11-29Polymorphic forms of icotinib maleate and uses thereof
#11 | 2015-11-05 ✅ Patent 9,617,257 granted on 2017-04-11Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors
#12 | 2014-11-20 ✅ Patent 9,085,588 granted on 2015-07-21Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof
#13 | 2013-08-08 ✅ Patent 9,487,570 granted on 2016-11-08Glucagon like peptide analogs, composition, and method of use
#14 | 2013-05-16 ✅ Patent 9,242,991 granted on 2016-01-26Substituted fused heterocycles as c-Met tyrosine kinase inhibitors
Also check out Betta Pharmaceuticals Co., Ltd.'s (Hangzhou, China) applicant profile with 9 patent applications submitted.
130960 ⎘